Advertisement

Investigational New Drugs

, Volume 30, Issue 3, pp 1144–1149 | Cite as

A randomized phase II study of recombinant human endostatin plus gemcitabine/cisplatin compared with gemcitabine/cisplatin alone as first-line therapy in advanced non-small-cell lung cancer

  • Xin Zhao
  • Kai Mei
  • Xiaohong Cai
  • Jing Chen
  • Jingrui Yu
  • Chengya Zhou
  • Qiu Li
PHASE II STUDIES

Abstract

Purpose Studies indicate that recombinant human endostatin (rh-endostatin) can inhibit tumor endothelial cell proliferation, angiogenesis, and tumor growth. This study assessed the efficacy of the combination of standard gemcitabine plus cisplatin chemotherapy with rh-endostatin in patients with non-small-cell lung cancer (NSCLC). Patients and Methods Chemotherapy-naive patients with stage IIIB to IV NSCLC were randomly (1:1) assigned to receive gemcitabine/cisplatin chemotherapy alone or with 7.5 mg/ m2 of intravenously rh-endostatin on days 1 to 14 of each 3-week cycle. The primary end point was objective response rate (ORR). Results Baseline characteristics were similar between treatment arms. The best ORRs for rh-endostatin arm (n = 33) and chemotherapy-alone arm were 37.5% (95% CI: 21.3 to 47.2%) and 28.6% (95% CI: 19.8 to 37.6%), respectively. Median survival was 12.4 months in the rh-endostatin arm and 9.8 months in the chemotherapy-alone arm, and 1-year survival was 51.6% and 38.7%, respectively. Mild palpitions, diarrhea, and liver dysfunction were the most common rh-endostatin-related adverse events. Grade 3/4 hematological toxicities were all reported similar for patients in the two arms. Conclusion The addition of rh-endostatin to gemcitabine plus cisplatin chemotherapy for first-line treatment of NSCLC improves objective response and may improve survival.

Keywords

Toxicity Chemotherapy Cancer Response rate Non-small-cell lung cancer 

Notes

Acknowledgements

The authors wish to thank all the patients who chose to participate in this trial.

References

  1. 1.
    Parkin DM, Bray F, Ferlay J et al (2005) Global cancer statistics, 2002. CA Cancer J Clin 55:74–108PubMedCrossRefGoogle Scholar
  2. 2.
    Ardizzoni A, Boni L, Tiseo M et al (2007) Cisplatin- versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data meta-analysis. J Natl Cancer Inst 99:847–857PubMedCrossRefGoogle Scholar
  3. 3.
    Folkman J (1971) Tumor angiogenesis: therapeutic implications. N Engl J Med 285:1182–1186PubMedCrossRefGoogle Scholar
  4. 4.
    Italiano JE Jr, Richardson JL, Patel-Hett S et al (2008) Angiogenesis is regulated by a novel mechanism: pro- and antiangiogenic proteins are organized into separate platelet granules and differentially released. Blood 111:1227–1233PubMedCrossRefGoogle Scholar
  5. 5.
    Tosetti F, Ferrari N, De Flora S et al (2002) ‘Angioprevention’: angiogenesis is a common and key target for cancer chemopreventive agents. FASEB J 16:2–14PubMedCrossRefGoogle Scholar
  6. 6.
    Boehle AS, Kurdow R, Schulze M et al (2001) Human endostatin inhibits growth of human non-small-cell lung cancer in a murine xenotransplant model. Int J Cancer 94:420–428PubMedCrossRefGoogle Scholar
  7. 7.
    Iizasa T, Chang H, Suzuki M, et al (2005) Expression of collagen XVIII in non-small cell lung carcinoma and its prognostic value. AACR Meeting Abstracts, 944Google Scholar
  8. 8.
    Ni Q, Ji H, Zhao Z et al (2009) Endostar, a modified endostatin inhibits non small cell lung cancer cell in vitro invasion through osteopontin-related mechanism. Eur J Pharmacol 614:1–6PubMedCrossRefGoogle Scholar
  9. 9.
    Sun Y, Wang J, Liu Y, et al (2005) Results of phase III trial of rh-endostatin (YH-16) in advanced non-small cell lung cancer (NSCLC) patients. ASCO Meeting Abstracts :7138Google Scholar
  10. 10.
    Han B, Xiu Q, Wang H, et al (2008) Rh-endostatin injection plus paclitaxel and carboplatin therapy for non-small-cell lung cancer: randomized, double-blind, placebo-controlled, multicentre study. ASCO Meeting Abstracts :19126Google Scholar
  11. 11.
    Le Chevalier T, Scagliotti G, Natale R et al (2005) Efficacy of gemcitabine plus platinum chemotherapy compared with other platinum containing regimens in advanced non-small-cell lung cancer: a meta-analysis of survival outcomes. Lung Cancer 47:69–80PubMedCrossRefGoogle Scholar
  12. 12.
    Arrieta O, González-De la Rosa CH, Aréchaga-Ocampo E et al (2010) Randomized phase II trial of all-trans-retinoic acid with chemotherapy based on paclitaxel and cisplatin as first-line treatment in patients with advanced non-small-cell lung cancer. J Clin Oncol 28:3463–3471PubMedCrossRefGoogle Scholar
  13. 13.
    Schiller JH, Harrington D, Belani CP et al (2002) Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346:92–98PubMedCrossRefGoogle Scholar
  14. 14.
    Sandler A, Gray R, Perry MC et al (2006) Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355:2542–2550PubMedCrossRefGoogle Scholar
  15. 15.
    Reck M, von Pawel J, Zatloukal P et al (2009) Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non–small-cell lung cancer: AVAiL. J Clin Oncol 27:1227–1234PubMedCrossRefGoogle Scholar
  16. 16.
    Lynch TJ, Patel T, Dreisbach L et al (2010) Cetuximab and first-line taxane/carboplatin chemotherapy in advanced non-small-cell lung cancer: results of the randomized multicenter phase III trial BMS099. J Clin Oncol 28:911–917PubMedCrossRefGoogle Scholar
  17. 17.
    Pirker R, Pereira JR, Szczesna A et al (2009) Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomized phase III trial. Lancet 373:1525–1531PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  • Xin Zhao
    • 1
  • Kai Mei
    • 1
  • Xiaohong Cai
    • 1
  • Jing Chen
    • 1
  • Jingrui Yu
    • 1
  • Chengya Zhou
    • 1
  • Qiu Li
    • 2
  1. 1.The Department of Medical OncologySichuan Cancer HospitalChengduChina
  2. 2.The Department of Medical Oncology, Cancer Center, State Key Laboratory of Biotherapy, West China HospitalSichuan UniversityChengduChina

Personalised recommendations